Table 4.
Treatments Received by Patients Prior to High-Dose IL-2 Therapy
| Disease | Treatment | % of Patients1 |
|---|---|---|
| Melanoma | Chemotherapy | 23–100% |
| Hormone Therapy | 1–3% | |
| Immunotherapy | 30–35% | |
| Radiation | 13–35% | |
| Surgery | 96% | |
| Melanoma and RCC2 | Brain Radiosurgery | 25% |
| Surgery | 90% | |
| Chemotherapy | 10% | |
| Immunotherapy | 40% | |
| RCC | Nephrectomy | 74–94% |
| Immunotherapy | 4–18% | |
| Chemotherapy | 3–7% | |
| Hormone | 4% | |
| Radiation | 10% |
Abbreviations: IL-2, Interleukin-2; RCC, Renal Cell Carcinoma.
1
: Percentages may add up to more than 100% because many patients receive multiple therapies prior to IL-2
2
: This study did not differentiate between melanoma and RCC patients when reporting demographic variables